Snaidero N, Simons M. Myelination at a glance. J Cell Sci. 2014;127(Pt 14):2999–3004.
CAS PubMed Article Google Scholar
Philips T, Rothstein JD. Oligodendroglia: metabolic supporters of neurons. J Clin Invest. 2017;127(9):3271–80.
PubMed PubMed Central Article Google Scholar
Pohl HB, Porcheri C, Mueggler T, Bachmann LC, Martino G, Riethmacher D, Franklin RJ, Rudin M, Suter U. Genetically induced adult oligodendrocyte cell death is associated with poor myelin clearance, reduced remyelination, and axonal damage. J Neurosci. 2011;31(3):1069–80.
CAS PubMed PubMed Central Article Google Scholar
Ghosh A, Manrique-Hoyos N, Voigt A, Schulz JB, Kreutzfeldt M, Merkler D, Simons M. Targeted ablation of oligodendrocytes triggers axonal damage. PLoS ONE. 2011;6(7): e22735.
CAS PubMed PubMed Central Article Google Scholar
Oluich LJ, Stratton JA, Xing YL, Ng SW, Cate HS, Sah P, Windels F, Kilpatrick TJ, Merson TD. Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination. J Neurosci. 2012;32(24):8317–30.
CAS PubMed PubMed Central Article Google Scholar
Alizadeh A, Dyck SM, Karimi-Abdolrezaee S. Myelin damage and repair in pathologic CNS: challenges and prospects. Front Mol Neurosci. 2015;8:35.
PubMed PubMed Central Article CAS Google Scholar
Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221–31.
Stys PK, Zamponi GW, van Minnen J, Geurts JJ. Will the real multiple sclerosis please stand up? Nat Rev Neurosci. 2012;13(7):507–14.
CAS PubMed Article Google Scholar
Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019;26(1):27–40.
CAS PubMed Article Google Scholar
Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol. 2004;55(4):458–68.
Prineas JW, Kwon EE, Cho ES, Sharer LR, Barnett MH, Oleszak EL, Hoffman B, Morgan BP. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol. 2001;50(5):646–57.
CAS PubMed Article Google Scholar
Ransohoff RM. Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat Neurosci. 2012;15(8):1074–7.
CAS PubMed PubMed Central Article Google Scholar
Lassmann H, Bradl M. Multiple sclerosis: experimental models and reality. Acta Neuropathol. 2017;133(2):223–44.
CAS PubMed Article Google Scholar
Oleszak EL, Chang JR, Friedman H, Katsetos CD, Platsoucas CD. Theiler’s virus infection: a model for multiple sclerosis. Clin Microbiol Rev. 2004;17(1):174–207.
CAS PubMed PubMed Central Article Google Scholar
Robinson AP, Harp CT, Noronha A, Miller SD. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol. 2014;122:173–89.
PubMed PubMed Central Article Google Scholar
Skundric DS. Experimental models of relapsing-remitting multiple sclerosis: current concepts and perspective. Curr Neurovasc Res. 2005;2(4):349–62.
CAS PubMed Article Google Scholar
Sriram S, Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol. 2005;58(6):939–45.
CAS PubMed Article Google Scholar
Zendedel A, Beyer C, Kipp M. Cuprizone-induced demyelination as a tool to study remyelination and axonal protection. J Mol Neurosci. 2013;51(2):567–72.
CAS PubMed Article Google Scholar
Blakemore WF, Franklin RJ. Remyelination in experimental models of toxin-induced demyelination. Curr Top Microbiol Immunol. 2008;318:193–212.
Vega-Riquer JM, Mendez-Victoriano G, Morales-Luckie RA, Gonzalez-Perez O. Five decades of cuprizone, an updated model to replicate demyelinating diseases. Curr Neuropharmacol. 2019;17(2):129–41.
CAS PubMed PubMed Central Article Google Scholar
Hooijmans CR, Hlavica M, Schuler FAF, Good N, Good A, Baumgartner L, Galeno G, Schneider MP, Jung T, de Vries R, et al. Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis. Sci Rep. 2019;9(1):822.
PubMed PubMed Central Article CAS Google Scholar
Plemel JR, Liu WQ, Yong VW. Remyelination therapies: a new direction and challenge in multiple sclerosis. Nat Rev Drug Discov. 2017;16(9):617–34.
CAS PubMed Article Google Scholar
Nilsson G, Erdtman H, Lindstedt G, Kinell P. A new colour reaction on copper and certain carbonyl compounds. Acta Chem Scand. 1950;4:205–205.
Carlton WW. Studies on the induction of hydrocephalus and spongy degeneration by cuprizone feeding and attempts to antidote the toxicity. Life Sci. 1967;6(1):11–9.
CAS PubMed Article Google Scholar
Carlton WW. Response of mice to the chelating agents sodium diethyldithiocarbamate, alpha-benzoinoxime, and biscyclohexanone oxaldihydrazone. Toxicol Appl Pharmacol. 1966;8(3):512–21.
CAS PubMed Article Google Scholar
Suzuki K. Giant hepatic mitochondria: production in mice fed with cuprizone. Science. 1969;163(3862):81–2.
CAS PubMed Article Google Scholar
Kesterson JW, Carlton WW. Monoamine oxidase inhibition and the activity of other oxidative enzymes in the brains of mice fed cuprizone. Toxicol Appl Pharmacol. 1971;20(3):386–95.
CAS PubMed Article Google Scholar
Venturini G. Enzymic activities and sodium, potassium and copper concentrations in mouse brain and liver after cuprizone treatment in vivo. J Neurochem. 1973;21(5):1147–51.
CAS PubMed Article Google Scholar
Acs P, Selak MA, Komoly S, Kalman B. Distribution of oligodendrocyte loss and mitochondrial toxicity in the cuprizone-induced experimental demyelination model. J Neuroimmunol. 2013;262(1–2):128–31.
CAS PubMed Article Google Scholar
Hoppel CL, Tandler B. Biochemical effects of cuprizone on mouse liver and heart mitochondria. Biochem Pharmacol. 1973;22(18):2311–8.
CAS PubMed Article Google Scholar
Carlton WW. Spongiform encephalopathy induced in rats and guinea pigs by cuprizone. Exp Mol Pathol. 1969;10(3):274–87.
CAS PubMed Article Google Scholar
Silvestroff L, Bartucci S, Pasquini J, Franco P. Cuprizone-induced demyelination in the rat cerebral cortex and thyroid hormone effects on cortical remyelination. Exp Neurol. 2012;235(1):357–67.
CAS PubMed Article Google Scholar
Oakden W, Bock NA, Al-Ebraheem A, Farquharson MJ, Stanisz GJ. Early regional cuprizone-induced demyelination in a rat model revealed with MRI. NMR Biomed. 2017;30(9):e3743.
Adamo AM, Paez PM, Escobar Cabrera OE, Wolfson M, Franco PG, Pasquini JM, Soto EF. Remyelination after cuprizone-induced demyelination in the rat is stimulated by apotransferrin. Exp Neurol. 2006;198(2):519–29.
CAS PubMed Article Google Scholar
Kanno T, Sasaki S, Yamada N, Kawasako K, Tsuchitani M. Hexachlorophene and cuprizone induce the spongy change of the developing rat brain by different mechanisms: the role of 2’, 3’-cyclic nucleotide 3’-phosphodiesterase (CNPase). J Vet Med Sci. 2012;74(7):837–43.
CAS PubMed Article Google Scholar
Buyukmihci N, Goehring-Harmon F, Marsh RF. Retinal degeneration during clinical scrapie encephalopathy in hamsters. J Comp Neurol. 1982;205(2):153–60.
CAS PubMed Article Google Scholar
Kimberlin RH, Collis SC, Walker CA. Profiles of brain glycosidase activity in cuprizone-fed Syrian hamsters and in scrapie-affected mice, rats, Chinese hamsters and Syrian hamsters. J Comp Pathol. 1976;86(1):135–42.
CAS PubMed Article Google Scholar
Chen Z, Chen JT, Johnson M, Gossman ZC, Hendrickson M, Sakaie K, Martinez-Rubio C, Gale JT, Trapp BD. Cuprizone does not induce CNS demyelination in nonhuman primates. Ann Clin Transl Neurol. 2015;2(2):208–13.
CAS PubMed Article Google Scholar
Kondo A, Nakano T, Suzuki K. Blood-brain barrier permeability to horseradish peroxidase in twitcher and cuprizone-intoxicated mice. Brain Res. 1987;425(1):186–90.
CAS PubMed Article Google Scholar
Bakker DA, Ludwin SK. Blood-brain barrier permeability during Cuprizone-induced demyelination. Implications for the pathogenesis of immune-mediated demyelinating diseases. J Neurol Sci. 1987;78(2):125–37.
留言 (0)